Table 6.
Tacro AUC exposure values compliances within therapeutic ranges in patients with kidney alterations.
| Number of Subjects with IFTA | 1–5 Years (Tacro + MMF) |
>5 Years (Tacro + MMF) |
1–5 Years (Tacro) |
>5 Years (Tacro) |
Total | |
|---|---|---|---|---|---|---|
| 17 (23.6%) Out of 72 |
8 * (18.2%) Out of 44 |
3 (30.0%) Out of 10 |
6 (33.3%) Out of 18 |
34 (23.6%) Out of 144 |
||
| Therapeutic range | <120 µg/h/L | 5 (29.4%) | 4 (50.0%) | 2 (66.7%) | 3 (50.0%) | 14 (9.7%) |
| 120–150 µg/h/L | 8 (47.1%) | 1 (12.5%) | 1 (33.3%) | 1 (16.7%) | 11 (7.6%) | |
| >150 µg/h/L | 4 (23.5%) | 3 (37.5%) | - | 2 (33.3%) | 9 (6.3%) |
IFTA—interstitial fibrosis and tubular atrophy; MMF—mycophenolate mofetil; Tacro—tacrolimus; NA—not applicable. * 1 of the subjects experienced an adverse drug reaction.